Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study

EJNMMI Research

Table 2 ¹⁸F-florbetapir SUVRs in the healthy controls (HCs) and patients with major depressive disorder (MDD) with differing levels of treatment resistance in seven cortical VOIs and the global cortex

Region	HCs	MDD patients		P value
Region	HCs	Mild treatment resistance	Moderate-to-severe treatment resistance	P value
Frontal				0.365
Mean ± SD	1.09 ± 0.09	1.12 ± 0.11	1.11 ± 0.15
Median (IQR)	1.07 (1.04–1.16)	1.09 (1.06–1.15)	1.07 (1.03–1.15)
Anterior cingulate				0.606
Mean ± SD	1.21 ± 0.11	1.24 ± 0.12	1.21 ± 0.15
Median (IQR)	1.18 (1.13–1.30)	1.24 (1.16–1.33)	1.22 (1.11–1.29)
Posterior cingulate				0.251
Mean ± SD	1.31 ± 0.12	1.31 ± 0.16	1.36 ± 0.16
Median (IQR)	1.28 (1.21–1.43)	1.29 (1.24–1.41)	1.35 (1.27–1.44)
Occipital				0.284
Mean ± SD	1.15 ± 0.08	1.18 ± 0.08	1.21 ± 0.13
Median (IQR)	1.16 (1.09–1.21)	1.17 (1.14–1.23)	1.19 (1.12–1.24)
Parietal				0.032*
Mean ± SD	1.01 ± 0.08	1.08 ± 0.11	1.11 ± 0.15^a*
Median (IQR)	1.03 (0.94–1.06)	1.06 (1.00–1.17)	1.08 (1.02–1.14)
Precuneous				0.201
Mean ± SD	1.02 ± 0.08	1.06 ± 0.1	1.10 ± 0.17
Median (IQR)	1.02 (0.95–1.09)	1.04 (1.00–1.10)	1.06 (0.99–1.13)
Temporal				0.693
Mean ± SD	1.03 ± 0.06	1.02 ± 0.07	1.03 ± 0.12
Median (IQR)	1.02 (1.00–1.07)	1.01 (0.99–1.04)	1.00 (0.95–1.08)
Global				0.52
Mean ± SD	1.13 ± 0.07	1.15 ± 0.09	1.16 ± 0.13
Median (IQR)	1.11 (1.07–1.16)	1.13 (1.11–1.19)	1.14 (1.09–1.18)